Penny Grewal Daumerie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Penny Grewal Daumerie has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Abdallah Mkopi
Ifakara Health Institute, Ifakara, Tanzania
1 shared publication - Allan Batte
Programme for Accessible Health Communication and Education-PACE, Kampala, Uganda
1 shared publication - Ambrose Talisuna
World Wide Antimalarial Resistance Network (WWARN), Malaria Public Health Department, University of Oxford/KEMRI/Wellcome Trust Research Programme, PO Box 43640, 00100, Nairobi, Kenya
1 shared publication - Amuri Baraka
Ifakara Health Institute, Ifakara, Tanzania
1 shared publication - Andrew Balyeku
Medicines for Malaria Venture-MMV, PO Box 1826 20, rte de Pré-Bois, Geneva 15, 1215, Switzerland
1 shared publication - Angela Bonabana
Uganda National Drug Authority-NDA, Kampala, Uganda
1 shared publication
Latest Publications
- Open Access
- 29 October 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 356
Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.
- 29 October 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 356
Open AccessClosing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.
- Open Access
- 22 December 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 80
Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study
Directly observed therapy (DOT) remains the cornerstone of the global tuberculosis (TB) control strategy. Tanzania, one of the 22 high-burden countries regarding TB, changed the first-line treatment regimen to contain rifampicin-containing fixed-dose combination for the full 6 months of treatment. As daily health facility-based DOT for this long period is not feasible for the patient, nor for the health system, Tanzania introduced patient centred treatment (PCT). PCT allows patients to choose for daily DOT at a health facility or at their home by a supporter of choice. The introduction of fixed dose combinations in the intensive and continuation phase made PCT feasible by eliminating the risk of selective drug taking by patients and reducing the number of tablets to be taken. The approach was tested in three districts with the objective to assess the effect of this strategy on TB treatment outcomes
- 22 December 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 80
Open AccessPatient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study
Directly observed therapy (DOT) remains the cornerstone of the global tuberculosis (TB) control strategy. Tanzania, one of the 22 high-burden countries regarding TB, changed the first-line treatment regimen to contain rifampicin-containing fixed-dose combination for the full 6 months of treatment. As daily health facility-based DOT for this long period is not feasible for the patient, nor for the health system, Tanzania introduced patient centred treatment (PCT). PCT allows patients to choose for daily DOT at a health facility or at their home by a supporter of choice. The introduction of fixed dose combinations in the intensive and continuation phase made PCT feasible by eliminating the risk of selective drug taking by patients and reducing the number of tablets to be taken. The approach was tested in three districts with the objective to assess the effect of this strategy on TB treatment outcomes